Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
Abstract Introduction An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data. Methods We developed a Markov state transition model of AD to estimate the cost effectivene...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12256 |
| _version_ | 1797949008830791680 |
|---|---|
| author | Pranay Sinha Joshua A. Barocas |
| author_facet | Pranay Sinha Joshua A. Barocas |
| author_sort | Pranay Sinha |
| collection | DOAJ |
| description | Abstract Introduction An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data. Methods We developed a Markov state transition model of AD to estimate the cost effectiveness of aducanumab compared to standard of care (SOC) over a 5‐year time horizon for a cohort of persons aged 65 with mild AD. Outcomes included quality adjusted life years (QALYs), discounted costs, and incremental cost‐effectiveness ratios (ICERs). We performed sensitivity analyses to address uncertainty. Results Over 5 years, the incremental cost of aducanumab compared to SOC was $179,890. Aducanumab resulted in 0.47 QALYs gained compared to SOC. The ICER for aducanumab compared to SOC was $383,080/QALY. In threshold analysis, aducanumab became cost‐effective at $22,820/year. Discussion Aducanumab is not cost‐effective at the estimated price of $56,000 even under ideal circumstances in which it completely halts AD progression. |
| first_indexed | 2024-04-10T21:52:35Z |
| format | Article |
| id | doaj.art-bb7119e721764303ac71e9a32db2a7c6 |
| institution | Directory Open Access Journal |
| issn | 2352-8737 |
| language | English |
| last_indexed | 2024-04-10T21:52:35Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj.art-bb7119e721764303ac71e9a32db2a7c62023-01-18T11:41:04ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12256Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list pricePranay Sinha0Joshua A. Barocas1Section of Infectious Diseases Boston Medical Center (BMC) Boston Massachusetts USADivisions of General Internal Medicine and Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado USAAbstract Introduction An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data. Methods We developed a Markov state transition model of AD to estimate the cost effectiveness of aducanumab compared to standard of care (SOC) over a 5‐year time horizon for a cohort of persons aged 65 with mild AD. Outcomes included quality adjusted life years (QALYs), discounted costs, and incremental cost‐effectiveness ratios (ICERs). We performed sensitivity analyses to address uncertainty. Results Over 5 years, the incremental cost of aducanumab compared to SOC was $179,890. Aducanumab resulted in 0.47 QALYs gained compared to SOC. The ICER for aducanumab compared to SOC was $383,080/QALY. In threshold analysis, aducanumab became cost‐effective at $22,820/year. Discussion Aducanumab is not cost‐effective at the estimated price of $56,000 even under ideal circumstances in which it completely halts AD progression.https://doi.org/10.1002/trc2.12256aducanumabAlzheimer's diseasecost‐effectivenessdementia |
| spellingShingle | Pranay Sinha Joshua A. Barocas Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price Alzheimer’s & Dementia: Translational Research & Clinical Interventions aducanumab Alzheimer's disease cost‐effectiveness dementia |
| title | Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price |
| title_full | Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price |
| title_fullStr | Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price |
| title_full_unstemmed | Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price |
| title_short | Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price |
| title_sort | cost effectiveness of aducanumab to prevent alzheimer s disease progression at current list price |
| topic | aducanumab Alzheimer's disease cost‐effectiveness dementia |
| url | https://doi.org/10.1002/trc2.12256 |
| work_keys_str_mv | AT pranaysinha costeffectivenessofaducanumabtopreventalzheimersdiseaseprogressionatcurrentlistprice AT joshuaabarocas costeffectivenessofaducanumabtopreventalzheimersdiseaseprogressionatcurrentlistprice |